(Part 2) Beyond the Blues: SAMe, Methylation and Personalised Testing

The Methylation Cycle: Where SAMe Fits

S-adenosyl-methionine (SAMe) sits at the intersection of the one-carbon metabolism pathway, which is driven by dietary folate (B9) and vitamin B12. Folate or B12 deficiency reduces methionine regeneration, depleting SAMe. Elevated homocysteine, a marker of SAMe deficiency, accumulates and exerts neurotoxic effects via NMDA receptor activation and oxidative stress.^[1] MTHFR gene variants (particularly C677T) impair active folate conversion, reducing downstream SAMe production and predisposing to treatment-resistant depression.^[2]

Mechanistic Links Between Low SAMe and Depressive Symptoms

Neurotransmitter disruption: SAMe is essential for the methylation of catecholamines via Catechol-O-methyltransferase (COMT). When SAMe is low, COMT activity is compromised, disrupting dopamine, noradrenaline, and adrenaline catabolism. A landmark clinical study found that patients with elevated homocysteine had significantly reduced cerebrospinal fluid (CSF) levels of SAMe and all three monoamine metabolites: 5-HIAA (serotonin), HVA (dopamine), and MHPG (noradrenaline).^[3]
Epigenetic dysregulation: Low SAMe leads to DNA hypomethylation (with suppression of BDNF), mRNA hypomethylation (disrupting synaptic gene expression), and histone hypomethylation, all implicated in major depressive disorder (MDD).^[4][5]
Neuroinflammation: SAMe exerts anti-inflammatory effects by methylating DNA and histones to suppress pro-inflammatory cytokines. In states of SAMe depletion, this brake on neuroinflammation is reduced.^[4]

Clinical Evidence

As monotherapy vs. placebo: SAMe is significantly effective; overall effect size −0.65^[6]
As adjunct to SSRIs in non-responders: SAMe 1,600 mg/day produced a response rate of 36.1% vs. 17.6% placebo, and remission of 25.8% vs. 11.7% placebo^[4]
The World Federation of Societies of Biological Psychiatry (WFSBP) and CANMAT Clinician Guidelines suggest higher-dose SAMe may offer benefit when used as adjunct therapy for depression.^[7]

Key safety caution: SAMe can precipitate hypomania or mania in bipolar disorder and should be used with caution or avoided in this population.^[8]

Functional Assessment of SAMe Status

Indirect markers used clinically include:

Plasma homocysteine: elevated levels are a sensitive surrogate for functional SAMe deficiency^[3]
Serum and red cell folate, serum B12 and methylmalonic acid (MMA)
Methylation Profile by Doctors Data. At OT&P we use this test which allows us to measure SAMe levels in then blood
MTHFR genotyping (C677T, A1298C): identifies genetic predisposition to impaired methylation^[2]

Treatment of Low SAMe levels

SAMe can itself act as an antidepressant, as above, and has been used for this in the past. It is available as a pharmaceutical product in Hong Kong “Heptral”. It is also available as a nutritional supplement
Supplements of B12 and Folate are readily available. It is always best to give B Vitamins inn their activated form, ie Methyl B12, MTHF or Folinic Acid
The SAMe is an amino acid. Protein will increase levels and supplementing with Cysteine as NAC is helpful in raising SAMe levels

It’s Creatine Again!!

Creatine requires SAMe to be synthesized, and therefore can improve cognition, energy and mood in depressed patients. Some fun facts:

Creatine synthesis consumes up to 70% of all available SAMe methyl groups, making it the single largest consumer of SAMe in the body^[9]
Supplementing creatine spares SAMe: by reducing endogenous synthesis demand, dietary creatine increases available SAMe for neurotransmitter methylation (dopamine, serotonin, noradrenaline) and other one-carbon reactions^[10]
Conversely, when SAMe is low (e.g., in folate/B12 deficiency, alcohol-associated liver disease, MTHFR variants), creatine synthesis will be impaired^[11]
Strong preclinical evidence and growing clinical evidence support antidepressant effects of creatine, particularly as an adjunct to SSRIs and primarily in females^[12]
Creatine supplementation (3–5 g/day) accelerated SSRI response in women with Depression in an 8-week double-blind RCT^[13]

The Functional Medicine Workup for Depression

Rather than applying a one-size-fits-all protocol, functional medicine uses a comprehensive, personalised assessment:

Domain	Key Tests
Inflammatory markers	hsCRP, ESR, cytokine panel
Nutritional status	Vitamin D (25-OH), B12, folate, ferritin, zinc, magnesium, omega-3 index
Methylation/SAMe status	Homocysteine, MMA, red cell folate, MTHFR genotyping
Hormonal assessment	Full thyroid panel, sex hormones, DHEA-S
HPA axis	DUTCH test / salivary cortisol diurnal curve
Gut health	Comprehensive stool analysis (microbiome, dysbiosis markers, intestinal permeability)
Metabolic	Fasting glucose, insulin, HbA1c, homocysteine. Methylation Profile
Toxin exposure	Heavy metals, mould toxins (where clinically indicated)

Putting It All Together

A functional medicine approach to depression is not about replacing conventional care. Psychotherapy, medication, and psychiatric support remain critically important, particularly for moderate-to-severe depression.^[14]What functional medicine adds is a systematic investigation of the biological terrain that makes a person vulnerable to depression in the first place.

By addressing inflammation, restoring gut-brain axis integrity, correcting hormonal and nutritional imbalances, supporting HPA resilience, and optimising methylation capacity through SAMe and targeted B vitamin support, it becomes possible to treat the person, not just the symptom. Of course lifestyle and exercise are an integral part of any personalised program for depression

Depression is not a life sentence. For many patients, the answer lies not in a single prescription, but in the confluence of multiple small repairs to a system that has been asking for attention.

Dr Tim Trodd

Family Medicine, Functional Medicine, General Practice

MBBS (London)
DCH (London)
DRCOG (UK)
MRCGP (UK)
FHKAM (Family Medicine)

View Profile View Reports & Publications

Health Articles by Dr Tim Trodd

Interviews

References

Liwinski, T. and Lang, U.E. (2023) 'Folate and its significance in depressive disorders and suicidality: a comprehensive narrative review', Nutrients, 15(17), 3859. https://doi.org/10.3390/nu15173859 [europepmc.org]
Ginsberg, L.D., Oubre, A.Y. and Daoud, Y.A. (2011) 'L-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode', Innovations in Clinical Neuroscience, 8(1), pp. 19–28. [europepmc.org]
Bottiglieri, T., Laundy, M., Crellin, R., Toone, B.K., Carney, M.W.P. and Reynolds, E.H. (2000) 'Homocysteine, folate, methylation, and monoamine metabolism in depression', Journal of Neurology, Neurosurgery & Psychiatry, 69(2), pp. 228–232. https://doi.org/10.1136/jnnp.69.2.228 [jnnp.bmj.com]
Ullah, H., Khan, A., Rengasamy, K.R.R., Di Minno, A., Sacchi, R. and Daglia, M. (2022) 'The efficacy of S-adenosyl methionine and probiotic supplementation on depression: a synergistic approach', Nutrients, 14(13), 2751. https://doi.org/10.3390/nu14132751 [europepmc.org]
Yuan, M., Yang, B., Rothschild, G., Mann, J.J., Sanford, L.D., Tang, X., Huang, C., Wang, C. and Zhang, W. (2023) 'Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential', Signal Transduction and Targeted Therapy, 8(1), 309. https://doi.org/10.1038/s41392-023-01519-z [bibliograp...lumbia.edu]
Sharma, A., Gerbarg, P., Bottiglieri, T., Massoumi, L., Carpenter, L.L., Lavretsky, H., Muskin, P.R., Brown, R.P. and Mischoulon, D. (2017) 'S-adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research', The Journal of Clinical Psychiatry, 78(6), pp. e656–e667. https://doi.org/10.4088/JCP.16r11113 [europepmc.org]
Shane-McWhorter, L. (2025) S-adenosyl-L-methionine (SAMe). Merck Manual Professional Edition. Available at: https://www.merckmanuals.com/en-ca/professional/special-subjects/dietary-supplements/s-adenosyl-l-m… [merckmanuals.com]
National Center for Complementary and Integrative Health (NCCIH) (n.d.) S-adenosyl-L-methionine (SAMe): in depth. Available at: https://www.nccih.nih.gov/health/sadenosyllmethionine-same-in-depth [nccih.nih.gov]
Allen, P.J. (2012) 'Creatine metabolism and psychiatric disorders: does creatine supplementation have therapeutic value?', Neuroscience & Biobehavioral Reviews, 36(5), pp. 1442–1462. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3340488/ [pmc.ncbi.nlm.nih.gov]
Stead, L.M., Au, K.P., Jacobs, R.L., Brosnan, M.E. and Brosnan, J.T. (2001) 'Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate', American Journal of Physiology-Endocrinology and Metabolism, 281(5), pp. E1095–E1100. https://doi.org/10.1152/ajpendo.2001.281.5.E1095 [europepmc.org]
Barbier-Torres, L., Chhimwal, J., Mato, J.M. and Lu, S.C. (2025) 'Methionine adenosyltransferase 1A and S-adenosylmethionine in alcohol-associated liver disease', Antioxidants, 14(12), 1486. https://doi.org/10.3390/antiox14121486 [mdpi.com]
Juneja, K., Bhuchakra, H.P., Sadhukhan, S., Mehta, I., Niharika, A., Thareja, S., Nimmakayala, T. and Sahu, S. (2024) 'Creatine supplementation in depression: a review of mechanisms, efficacy, clinical outcomes, and future directions', Cureus, 16(10), e71638. https://doi.org/10.7759/cureus.71638 [scispace.com]
Lyoo, I.K., Yoon, S., Kim, T.-S., Hwang, J., Kim, J.E., Won, W., Bae, S. and Renshaw, P.F. (2012) 'A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder', American Journal of Psychiatry, 169(9), pp. 937–945. https://doi.org/10.1176/appi.ajp.2012.12010009 [pubmed.ncb...lm.nih.gov]
Maniaci, G., La Cascia, C., Giammanco, A., Ferraro, L., Sardella, Z., Bivona, G., Ciaccio, M. and La Barbera, D. (2021) 'Efficacy of a functional therapy program for depression and C-reactive protein: a pilot study', Clinical Neuropsychiatry, 18(4), pp. 188–195. https://doi.org/10.36131/cnfioritieditore20210402 [europepmc.org]